145 related articles for article (PubMed ID: 7903917)
21. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
[TBL] [Abstract][Full Text] [Related]
22. Perspectives on purine analogues.
Cheson BD
Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S109-16. PubMed ID: 9137964
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab.
Tobinai K; Watanabe T; Tanimoto K; Maruyama D; Nakata M; Itoh K; Morishima Y; Ogura M; Usui N; Kasai M; Terauchi T; Nawano S; Matsusako M; Matsuno Y; Nakamura S; Mori S; Ohashi Y
Cancer Sci; 2009 Jul; 100(7):1344-50. PubMed ID: 19432900
[TBL] [Abstract][Full Text] [Related]
24. Cladribine in indolent non-Hodgkin's lymphoma.
Sigal DS; Saven A
Expert Rev Anticancer Ther; 2008 Apr; 8(4):535-45. PubMed ID: 18402520
[TBL] [Abstract][Full Text] [Related]
25. Beyond hairy cell: the activity of cladribine in other hematologic malignancies.
Sigal DS; Miller HJ; Schram ED; Saven A
Blood; 2010 Oct; 116(16):2884-96. PubMed ID: 20634380
[TBL] [Abstract][Full Text] [Related]
26. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
[TBL] [Abstract][Full Text] [Related]
27. Concomitant hairy cell and acute myeloid leukemia.
Rimner T; Went P; Tichelli A; Gratwohl A
Eur J Haematol; 2006 Jan; 76(1):86-8. PubMed ID: 16343277
[TBL] [Abstract][Full Text] [Related]
28. [Clinical pharmacology of 2-chlorodeoxyadenosine (Cladribine)].
Góra-Tybor J; Robak T
Przegl Lek; 1996; 53(8):614-8. PubMed ID: 8999463
[TBL] [Abstract][Full Text] [Related]
29. [Chronic lymphatic leukemia. Peroral cladribine as primary treatment].
Gjedde SB; Juliusson G; Hansen MM
Ugeskr Laeger; 1996 Nov; 158(45):6432-4. PubMed ID: 8992677
[TBL] [Abstract][Full Text] [Related]
30. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years.
Else M; Ruchlemer R; Osuji N; Del Giudice I; Matutes E; Woodman A; Wotherspoon A; Swansbury J; Dearden C; Catovsky D
Cancer; 2005 Dec; 104(11):2442-8. PubMed ID: 16245328
[TBL] [Abstract][Full Text] [Related]
31. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
[TBL] [Abstract][Full Text] [Related]
32. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.
Robak T; Blonski JZ; Wawrzyniak E; Gora-Tybor J; Palacz A; Dmoszynska A; Konopka L; Warzocha K; Jamroziak K
Cancer; 2009 Jan; 115(1):94-100. PubMed ID: 19025975
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine.
Zinzani PL; Magagnoli M; Bendandi M; Tani M; Stefoni V; Cellini C; Poggi S; Piccioli M; Pileri S; Tura S
Haematologica; 2000 Sep; 85(9):922-5. PubMed ID: 10980629
[TBL] [Abstract][Full Text] [Related]
34. Cladribine. Ortho Biotech Inc.
Tortorella C; Rovaris M; Filippi M
Curr Opin Investig Drugs; 2001 Dec; 2(12):1751-6. PubMed ID: 11892941
[TBL] [Abstract][Full Text] [Related]
35. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
Bosly A; Keating MJ; Stasi R; Bradstock K
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
[TBL] [Abstract][Full Text] [Related]
36. Deoxycoformycin (pentostatin): clinical pharmacology, role in the chemotherapy of cancer, and use in other diseases.
Spiers AS
Haematologia (Budap); 1996; 27(2):55-84. PubMed ID: 14651224
[TBL] [Abstract][Full Text] [Related]
37. Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies.
Robak T; Korycka A; Robak E
Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):23-38. PubMed ID: 18221024
[TBL] [Abstract][Full Text] [Related]
38. Recent clinical trials of cladribine in hematological malignancies and autoimmune disorders.
Robak T; Wierzbowska A; Robak E
Rev Recent Clin Trials; 2006 Jan; 1(1):15-34. PubMed ID: 18393777
[TBL] [Abstract][Full Text] [Related]
39. Cladribine (2-chloro-2'-deoxyadenosine): new perspectives in clinical immunosuppression.
Górski A; Grieb P
Arch Immunol Ther Exp (Warsz); 1994; 42(1):11-2. PubMed ID: 7503626
[TBL] [Abstract][Full Text] [Related]
40. 2-Chloro-2'-deoxyadenosine--clinical, biochemical and pharmacokinetic considerations.
Liliemark J; Juliusson G
Arch Immunol Ther Exp (Warsz); 1994; 42(1):7-10. PubMed ID: 7503639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
